No Data
No Data
No Data
Dongwu Securities released a research report on April 23 stating that it maintains the purchase rating of Fangsheng Pharmaceuticals (603998.SH). The main reasons for the rating include: 1) the steady release of 338 strategic products, and the outstanding
Dongwu Securities released a research report on April 23 stating that it maintains the purchase rating of Fangsheng Pharmaceuticals (603998.SH). The main reasons for the rating include: 1) the steady release of 338 strategic products, and the outstanding performance of innovative traditional Chinese medicine varieties; 2) focusing on investment in R&D and innovation to reserve medium- to long-term growth momentum. (Mainichi Keizai Shimbun)
Fangsheng Pharmaceutical (603998): Steady release of strategic products and orderly optimization of the business structure
Key investment events: In 2023, the company's revenue was 1,629 billion yuan (-9.12%, down 9.12% year on year, same below), net profit to mother of 187 million yuan (-34.64%), net profit not attributable to mother 1.34 billion yuan
Fangsheng Pharmaceutical (603998): Focus on innovation in the main business and continue to unleash growth potential
Event: Fangsheng Pharmaceutical announced on April 20, 2024: In 2023, the company achieved operating income of 1,629 billion yuan, a year-on-year decrease of 9.12%; net profit to mother was 187 million yuan, a year-on-year decrease of 34.64 million yuan
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Fangsheng Pharmaceutical (603998): Implementing a “nucleation” development strategy and innovation to drive the continuous growth of the “338” product
Event: On April 19, 2024, the company released the 2023 Annual Report and the First Quarter 2024 Report. In 2023, the company achieved revenue of 1,629 billion yuan, a year-on-year decrease of 9.12%, achieving
Fangsheng Pharmaceutical (603998.SH): Net profit of 70.19 million yuan in the first quarter increased 10.04% year-on-year
On April 19, Ge Longhui Pharmaceutical (603998.SH) released its first quarter report. Operating revenue was 438 million yuan, up 0.37% year on year, net profit of 70.19 million yuan, up 10.04% year on year, after deducting non-net profit of 53.8976 million yuan, up 9.61% year on year, with basic earnings of 0.16 yuan per share.
No Data